One-liner: “1910 Genetics develops a multimodal AI platform for drug discovery, targeting pharmaceutical and technology partners.”
Company slogan: Advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation.
Positioning: A biotechnology company focused on integrating AI with laboratory automation for drug discovery.
Description: “1910 Genetics is the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. We integrate AI with three proprietary data streams – computational data, wet lab proxy biological data, and wet lab ground truth biological data – to deliver novel drug candidates and software solutions to leading pharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer.
We are backed by leading investors including M12 – Microsoft’s Venture Fund, Playground Global, Sam Altman, Y Combinator, FoundersX Ventures, Scientia Ventures, and many others.”
Employees: 34
Website: Visit websiteHeadquarters: “Boston, MA”
Ownership: Privately Held
Founded: 2018
Company type: AI company
Use cases: “drug discovery, neurological diseases, autoimmune diseases, cancer”
Pricing: subscription-based
Client sector: pharmaceutical and technology partners
Business model: subscription
Products: “multimodal AI platform, software solutions for drug candidates”
Is API available: no
Website title: Home — 1910 Genetics
Website description: none
Linkedin: https://www.linkedin.com/company/1910genetics
Youtube: –
Instagram: –
Facebook: –
Twitter: https://twitter.com/1910genetics
Crunchbase: https://www.crunchbase.com/organization/1910-genetics
Email: –